Kissei Pharmaceutical Co (JP:4547) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kissei Pharmaceutical Co. has announced that its GnRH antagonist YSELTY, developed for treating endometriosis, has been approved for this additional indication by the European Commission. This approval, which follows a positive opinion from the Committee for Medicinal Products for Human Use, allows YSELTY to expand its market presence in Europe. Despite this development, the company’s financial forecast for the fiscal year remains largely unchanged.
For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.
